Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors

A compound according to Formula (I):

• or a pharmaceutically-acceptable salt thereof, wherein:
• X1 is selected from O and NR6;
• provided when X1 is NR6, R5 and R6 together with the nitrogen atom and the adjacent carbon atom to which they are respectively attached form a heterocyclic ring comprising carbon atoms and zero to 3 additional heteroatoms selected from N, NR8, O, S and substituted with 1-5 R10;
• R1 is selected from C1-4alkyl (optionally substituted with F, Cl, Br, OH, CN, and NRaRa), —(CRdRd)r-carbocyclyl substituted with 0-5 R11, and —(CRdRd)r-heterocyclyl comprising carbon atoms and 1 to 4 heteroatoms selected from N, NR9, O, S, and substituted with 0-5 R11;
• R2 is selected from H, C1-4alkyl, F, Cl, Br, CN, aryl, and heteroaryl;
• R3 is selected from H and C1-4alkyl;
• R4 is selected from H, C1-4alkyl F, Cl, Br, and CN;
• R5 is selected from H, C1-4alkyl substituted with 0-4 Re, —(CH2)r—C3-6 carbocyclyl substituted with 0-4 Re, and —(CH2)r-heterocyclyl comprising carbon atoms and 1 to 3 heteroatoms selected from N, O, S, and substituted with 0-4 Re;
• R7 is aryl substituted with 0-3 Re;
• R8 is selected from H, C1-4 alkyl substituted with 0-3 Re, —(CH2)rCN, —(CH2)rORb, (CH2)rS(O)pRc, —(CH2)rC(═O)Rb, —(CH2)rNRaRa, —(CH2)rC(═O)NRaRa, —(CH2)rC(═O)—C1-4 alkyl substituted with 0-3 Re, —(CH2)rNRaC(═O)Rb, —(CH2)rNRaC(═O)ORb, —(CH2)rOC(═O)NRaRa, —(CH2)rNRaC(═O)NRaRa, —(CH2)rC(═O)ORb, —(CH2)rS(O)2NRaRa, —(CH2)rNRaS(O)2NRaRa, —(CH2)rNRaS(O)2Rc, (CH2)r-carbocyclyl substituted with 0-3 Re, and —(CH2)r-heterocyclyl substituted with 0-3 Re;
• R9 is selected from H, —C(═O)Rb, C1-6 alkyl substituted with 0-5 Re, —(CH2)r—C3-6carbocyclyl substituted with 0-5 Re, and —(CH2)r-heterocyclyl substituted with 0-5 Re;
• R10 is selected from H, C1-6alkyl substituted with 0-3 Re, —(CH2)rNRaRa, —(CH2)rC(═O)Rb, —(CH2)rC(═O)ORb, —(CH2)rC(═O)NRaRa, S(O)pRc, (CH2)r—C3-6 carbocyclyl substituted with 0-3 Re, and —(CH2)r-heterocyclyl substituted with 0-3 Re;
• R11, at each occurrence, is independently selected from H, F, Cl, Br, ═O, CN, NO2, —ORb, —S(O)pRc, —C(═O)Rb, —(CRdRd)rNRaRa, —(CRdRd)rC(═O)NRaRa, —NRaC(═O)Rb, —NRaC(═O)ORb, —OC(═O)NRaRa, —NRaC(═O)NRaRa, —(CRdRd)rC(═O)ORb, —S(O)2NRaRa, —NRaS(O)2NRaRa, —NRaS(O)2Rc, C1-6 alkyl substituted with 0-5 Re, —(CRdRd)r—C3-6carbocyclyl substituted with 0-5 Re, and —(CRdRd)r-heterocyclyl substituted with 0-5 Re;
• Ra, at each occurrence, is independently selected from H, CN, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)r—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)r-heterocyclyl substituted with 0-5 Re;
• or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re;
• Rb, at each occurrence, is independently selected from H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)r—C3-10carbocyclyl substituted with 0-5 Re, and —(CH2)r-heterocyclyl substituted with 0-5 Re;
• Rc, at each occurrence, is independently selected from C1-6 alkyl substituted with 0-5 Re, C2-6alkenyl substituted with 0-5 Re, C2-6alkynyl substituted with 0-5 Re, C3-6carbocyclyl substituted with 0-5 Re, and heterocyclyl substituted with 0-5 Re;
• Rd, at each occurrence, is independently selected from H and C1-4alkyl substituted with 0-5 Re;
• Re, at each occurrence, is independently selected from C1-6 alkyl substituted with 0-5 Rf, C2-6 alkenyl, C2-6 alkynyl, —(CH2)r—C3-6 cycloalkyl, F, Cl, Br, CN, NO2, ═O, CO2H, —(CH2)rORf, SRf, and —(CH2)rNRfRf;
• Rf, at each occurrence, is independently selected from H, F, C1-5 alkyl, C3-6 cycloalkyl, and phenyl, or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C1-4alkyl;
• p, at each occurrence, is independently selected from zero, 1, and 2;
• and
• r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.